Walgreens Boots Alliance — Q4 2024 Earnings Presentation
43 slides from Walgreens Boots Alliance's earnings presentation, Oct 15, 2024
Slide 1: Fourth Quarter and Fiscal 2024 Results
Fourth Quarter and Fiscal 2024 Results October 15, 2024 © 2024 Walgreens Boots Alliance, Inc. All rights reserved.
Slide 2: Safe Harbor and Non-GAAP
Safe Harbor and Non-GAAP Cautionary Note Regarding Forward-Looking Statements: All statements in this presentation that are not historical are forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These include, without limitat
Slide 3: Our Critical Focus: Stabilize core retail pharmacy to drive long-term value creation
Our Critical Focus: Stabilize core retail pharmacy to drive long- term value creation • Fiscal 2024 was a foundational year: − Built new executive leadership team − Achieved targets in cost management, working capital initiatives and capex reduction, and positive adjusted EBITDA1 in U.S. Healthcare
Slide 4: Our Guiding Principles and Goals
Our Guiding Principles and Goals Retail Pharmacy-Led Store Model Disciplined and Sustainable Financial Model • Trusted: Millions of face-to-face pharmacy • Stable Adjusted Operating Income1: Restructure interactions every day make us a valued partner reimbursement arrangements and establish a to our
Slide 5: 4Q & FY24 Results
4Q & FY24 Results Manmohan Mahajan Global Chief Financial Officer, WBA © 2024 Walgreens Boots Alliance, Inc. All rights reserved. 5
Slide 6: WBA 4Q24 Financial Highlights
Reported Fx Constant Fx1 4Q24 $ in millions (except EPS) B/(W) vs. 4Q23 B/(W) vs. 4Q23 Sales $37,547 + 6.0% + 6.1% Operating Income GAAP ($978) ($527) Adjusted1 $424 (37.9)% (37.7)% WBA 4Q24 Financial Net Earnings GAAP ($3,005) ($2,825) Highlights Adjusted1 $340 (41.0)% (40.8)% EPS GAAP ($3.48) ($3.
Slide 7: WBA FY24 Financial Highlights
Reported Fx Constant Fx1 FY24 $ in millions (except EPS) B/(W) vs. FY23 B/(W) vs. FY23 Sales $147,658 + 6.2% + 5.7% Operating Income GAAP ($14,076) ($7,195) Adjusted1 $2,624 (32.2)% (32.6)% WBA FY24 Financial Net Earnings GAAP ($8,636) ($5,556) Highlights Adjusted1 $2,491 (27.6)% (27.9)% EPS GAAP ($
Slide 8: U.S. Retail Pharmacy Financials
4Q24 B/(W) vs. 4Q23 FY24 B/(W) vs. FY23 $ in millions Sales $29,470 + 6.5% $115,778 + 5.0% Adj. gross profit1 $4,768 (7.7)% $20,854 (6.5)% U.S. Retail Adj. SG&A % of sales1 15.7% 1.3%p 16.5% 0.8%p Pharmacy Adj. operating income1 $220 (60.4)% $2,167 (41.3)% Financials Adj. operating margin1,2 0.5% (1
Slide 9: U.S. Pharmacy
4Q24 4Q24 FY24 FY24 4Q24 vs. 4Q23 | FY24 vs. FY23 Total Comparable1 Total Comparable1 Pharmacy sales + 9.6% + 11.7% + 8.2% + 9.8% Prescriptions + 1.5% + 2.5% + 1.2% + 2.0% Prescriptions ex. + 1.6% + 2.6% + 1.3% + 2.2% U.S. Pharmacy Immunizations • Comp pharmacy sales1 +11.7% primarily due to brand i
Slide 10: U.S. Retail
4Q24 FY24 4Q24 vs. 4Q23 | FY24 vs. FY23 Total retail sales (3.5)% (4.6)% Comparable retail sales1 (1.7)% (3.4)% • 4Q comp retail sales down 1.7%, reflecting a challenging retail environment and U.S. Retail continued channel shift − ~150 bps negative impact from discretionary categories including bea
Slide 11: International Financials
Constant Fx1 Constant Fx1 4Q24 FY24 $ in millions B/(W) vs. 4Q23 B/(W) vs. FY23 Sales $5,971 + 3.7% $23,552 + 3.2% Adj. gross profit1 $1,307 + 1.9% $5,027 + 3.4% Adj. SG&A % of sales1 18.0% (0.2)%p 18.0% (0.9)%p International Adj. operating income1 $231 (10.6)% $793 (16.9)% Financials Adj. operating
Slide 12: Boots UK Financials
4Q24 FY24 4Q24 vs. 4Q23 | FY24 vs. FY23 (constant Fx1) Pharmacy comp. sales1 + 10.0% + 4.9% Retail comp. sales1 + 6.2% + 6.9% Boots UK Financials • Strong retail comp sales1 growth of +6.2% in 4Q, with growth across all categories • 4Q Boots.com sales growth of +18.7% on a constant currency basis1,
Slide 13: U.S. Healthcare Financials
4Q24 B/(W) vs. 4Q23 FY24 B/(W) vs. FY23 $ in millions Sales $2,113 + $141 $8,345 + $1,775 Adj. gross profit1 $253 + $106 $812 + $398 Adj. SG&A1 ($236) ($6) ($946) + $34 Adj. operating U.S. Healthcare income (loss)1 $17 + $100 ($134) + $433 Financials Adj. EBITDA1 $65 + $94 $66 + $442 • 4Q sales of $
Slide 14: Cash Flow
B/(W) FY24 $ in millions vs. FY23 Operating cash flow $1,018 ($1,240) Cash capital expenditure ($1,381) $736 Free cash flow1,2 $23 ($642) • Operating cash flow negatively impacted by $934M in payments related to legal matters Cash Flow and $386M Boots Pension Plan Annuity premium contributions • Yea
Slide 15: FY25 Guidance
FY25 Guidance Manmohan Mahajan Global Chief Financial Officer, WBA © 2023 Walgreens Boots Alliance, Inc. All rights reserved. 15
Slide 16: FY25 focused on stabilizing the core business
FY25 focused on stabilizing the core business • FY25 adj. EPS1 guidance of $1.40-$1.80; key assumptions: − Reimbursement pressure continues; we are actively working to stabilize pharmacy margins − Expect similar challenging retail environment as in FY24; executing on several retail and operations in
Slide 17: Footprint optimization program expected to immediately improve core profitability
Footprint optimization program expected to immediately improve core profitability Store closures and timeline Financial impacts • Expecting to close ~1,200 locations1 over the next • Immediately cash flow accretive, net of closure three years, with ~500 in FY25 costs; benefits scale as underlying le
Slide 18: FY25 enterprise assumptions
FY25 enterprise assumptions FY25 Commentary $147.0 - $151.0B • Higher brand inflation and mix impacts in U.S. Sales • Partially offset by footprint optimization program • Reimbursement pressure, decline in retail sales • Absence of sale and leaseback contribution WBA AOI1 $1.6 - $2.0B • Lower Cencor
Slide 19: FY25 segment assumptions
FY25 segment assumptions FY25 Key assumptions • Expecting Rx script market growth 2.5% - 3% Sales $115.0 - $118.0B • Total vaccines slightly down vs. FY24 U.S. Retail • Projecting (2%) - (3%) retail comps with margin in line with prior year Pharmacy $0.9 - $1.2B • Store closures accretive to AOI1 an
Slide 20: Cash Flow & Capital Allocation
FY25 free cash flow1 key assumptions: • Year over year decline in sale-leaseback gains and Cencora equity earnings of ~$400M does not impact free cash flow1 • Working capital initiatives of ~$500M, driven by U.S. Retail Pharmacy • Capex expected to be lower than FY24 by at least $150M • Legal paymen
Slide 21: Closing Remarks
Closing Remarks Tim Wentworth Chief Executive Officer, WBA © 2024 Walgreens Boots Alliance, Inc. All rights reserved. 21
Slide 22: Conclusions
Conclusions • We have the right team and the right strategy • Our turnaround will take time but we are executing with urgency • We are focused on two guiding principles: − A store-based retail pharmacy-led operating model − A disciplined and sustainable economic model • Our priorities for fiscal 202
Slide 23: Q&A
Q&A © 2024 Walgreens Boots Alliance, Inc. All rights reserved. 23
Slide 24: Endnotes
Endnotes • Please see appendix for reconciliations of non-GAAP financial measures and related disclosures • The Company presents certain information related to current period operating results in “constant currency,” which is a non-GAAP financial measure. These amounts are calculated by translating
Slide 25: Appendix
Appendix The information on the following pages provides reconciliations of the supplemental non-GAAP financial measures, as defined under SEC rules, presented in this presentation and discussed on the related conference call to the most directly comparable financial measures calculated and presente
Slide 26: Reconciliation of Non-GAAP financial measures
Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions, except net debt ratio and lease adjusted net debt ratio) The Company defines net debt ratio as net debt divided by adjusted earnings before interest, tax,
Slide 27: Reconciliation of Non-GAAP financial measures
Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) NET LOSS TO ADJUSTED OPERATING INCOME, ADJUSTED EBITDA and ADJUSTED EBITDAR Fiscal 2024 Net loss (GAAP) $ (15,448) Post-tax earnings from other equity meth
Slide 28: Reconciliation of Non-GAAP financial measures
Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) 1 In the second quarter of fiscal 2024, the Company recorded $12.4 billion of non-cash impairment charges related to VillageMD goodwill. In the fourth quarter of fiscal
Slide 29: Reconciliation of Non-GAAP financial measures
Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions, except per share amounts) NET LOSS TO ADJUSTED NET EARNINGS AND DILUTED NET LOSS PER SHARE TO ADJUSTED DILUTED NET EARNINGS PER SHARE Three months ended Au
Slide 30: Reconciliation of Non-GAAP financial measures
Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions, except per share amounts) NET LOSS TO ADJUSTED NET EARNINGS AND DILUTED NET LOSS PER SHARE TO ADJUSTED DILUTED NET EARNINGS PER SHARE Three months ended Au
Slide 31: Reconciliation of Non-GAAP financial measures
Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions, except per share amounts) NET LOSS TO ADJUSTED NET EARNINGS AND DILUTED NET LOSS PER SHARE TO ADJUSTED DILUTED NET EARNINGS PER SHARE Three months ended Au
Slide 32: Reconciliation of Non-GAAP financial measures
Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) 1 In the second quarter of fiscal 2024, the Company recorded $12.4 billion of non-cash impairment charges related to VillageMD goodwill. In the fourth quarter of fiscal
Slide 33: Reconciliation of Non-GAAP financial measures
Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) 15 In fiscal 2024, the Company recorded a $2.2 billion non-cash charge due to recognition of a valuation allowance against certain U.S. and state deferred tax assets pri
Slide 34: Reconciliation of Non-GAAP financial measures
Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) Three months ended August 31, 2024 Walgreens Boots U.S. Retail Pharmacy 1 International U.S. Healthcare Corporate and Other Alliance, Inc. Sales $ 29,470 $
Slide 35: Reconciliation of Non-GAAP financial measures
Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) Three months ended August 31, 2023 Walgreens Boots U.S. Retail Pharmacy 1 International U.S. Healthcare Corporate and Other Alliance, Inc. Sales $ 27,666 $
Slide 36: Reconciliation of Non-GAAP financial measures
Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) Twelve months ended August 31, 2024 Walgreens Boots U.S. Retail Pharmacy 1 International U.S. Healthcare Corporate and Other Alliance, Inc. Sales $ 115,778
Slide 37: Reconciliation of Non-GAAP financial measures
Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) Twelve months ended August 31, 2023 Walgreens Boots U.S. Retail Pharmacy 1 International U.S. Healthcare Corporate and Other Alliance, Inc. Sales $ 110,314
Slide 38: Reconciliation of Non-GAAP financial measures
Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) 1 Operating loss for U.S. Retail Pharmacy includes equity earnings in Cencora. As a result of the two month reporting lag, operating loss for the three and
Slide 39: Reconciliation of Non-GAAP financial measures
Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) OPERATING LOSS TO ADJUSTED EBITDA FOR THE U.S. HEALTHCARE SEGMENT Three months ended August 31, Twelve months ended August 31, 2024 2023 2024 2023 1 Operat
Slide 40: Reconciliation of Non-GAAP financial measures
Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) EQUITY EARNINGS IN CENCORA Three months ended August 31, Twelve months ended August 31, 2024 2023 2024 2023 Equity earnings in Cencora (GAAP) $ 49 $ 65 $ 2
Slide 41: Reconciliation of Non-GAAP financial measures
Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) ADJUSTED EFFECTIVE TAX RATE Three months ended August 31, 2024 Three months ended August 31, 2023 (Loss) Earnings (Loss) earnings Income tax Income tax bef
Slide 42: Reconciliation of Non-GAAP financial measures
Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) FREE CASH FLOW Three months ended August 31, Twelve months ended August 31, 2024 2023 2024 2023 Net cash provided by operating activities (GAAP) $ 1,331 $
Slide 43: Supplemental Financial Information
Supplemental Financial Information Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) Sale-leaseback financial information Three months ended Twelve months ended August 31, 2024 Change vs. 4Q23 August 31, 2024 Change vs. FY23 U.S. Retail Pharmacy Gain
Walgreens Boots Alliance — Q4 2024 Earnings Presentation on 6ix